PMID- 10435596
OWN - NLM
STAT- MEDLINE
DCOM- 19990813
LR  - 20220330
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 18
IP  - 28
DP  - 1999 Jul 15
TI  - Localization of common deletion regions on 1p and 19q in human gliomas and their 
      association with histological subtype.
PG  - 4144-52
AB  - Allelic alterations of chromosomes 1 and 19 are frequent events in human diffuse 
      gliomas and have recently proven to be strong predictors of chemotherapeutic 
      response and prolonged survival in oligodendrogliomas (Cairncross et al., 1998; 
      Smith et al., submitted). Using 115 human diffuse gliomas, we localized regions 
      of common allelic loss on chromosomes 1 and 19 and assessed the association of 
      these deletion intervals with glioma histological subtypes. Further, we evaluated 
      the capacity of multiple modalities to detect these alterations, including loss 
      of heterozygosity (LOH), fluorescence in situ hybridization (FISH), and 
      comparative genomic hybridization (CGH). The correlation coefficients for 
      detection of 1p and 19q alterations, respectively, between modalities were: 0.98 
      and 0.87 for LOH and FISH, 0.79 and 0.60 for LOH and CGH, and 0.79 and 0.53 for 
      FISH and CGH. Minimal deletion regions were defined on 19q13.3 (D19S412-D19S596) 
      and 1p (D1S468-D1S1612). Loss of the 1p36 region was found in 18% of astrocytomas 
      (10/55) and in 73% (24/33) of oligodendrogliomas (P < 0.0001), and loss of the 
      19q13.3 region was found in 38% (21/55) of astrocytomas and 73% (24/33) of 
      oligodendrogliomas (P = 0.0017). Loss of both regions was found in 11% (6/55) of 
      astrocytomas and in 64% (21/33) of oligodendrogliomas (P < 0.0001). All gliomas 
      with LOH on either 1p or 19q demonstrated loss of the corresponding FISH probe, 
      1p36 or 19q13.3, suggesting not only locations of putative tumor suppressor 
      genes, but also a simple assay for assessment of 1p and 19q alterations as 
      diagnostic and prognostic markers.
FAU - Smith, J S
AU  - Smith JS
AD  - Division of Laboratory Genetics, Mayo Clinic and Foundation, Rochester, Minnesota 
      55905, USA.
FAU - Alderete, B
AU  - Alderete B
FAU - Minn, Y
AU  - Minn Y
FAU - Borell, T J
AU  - Borell TJ
FAU - Perry, A
AU  - Perry A
FAU - Mohapatra, G
AU  - Mohapatra G
FAU - Hosek, S M
AU  - Hosek SM
FAU - Kimmel, D
AU  - Kimmel D
FAU - O'Fallon, J
AU  - O'Fallon J
FAU - Yates, A
AU  - Yates A
FAU - Feuerstein, B G
AU  - Feuerstein BG
FAU - Burger, P C
AU  - Burger PC
FAU - Scheithauer, B W
AU  - Scheithauer BW
FAU - Jenkins, R B
AU  - Jenkins RB
LA  - eng
GR  - CA50905/CA/NCI NIH HHS/United States
GR  - CA50910/CA/NCI NIH HHS/United States
GR  - CA64898/CA/NCI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
SB  - IM
MH  - Astrocytoma/genetics/pathology
MH  - Brain Neoplasms/*genetics/pathology
MH  - Chromosomes, Human, Pair 1/*genetics/ultrastructure
MH  - Chromosomes, Human, Pair 19/*genetics/ultrastructure
MH  - Glioma/classification/*genetics/pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Loss of Heterozygosity
MH  - Oligodendroglioma/genetics/pathology
MH  - *Sequence Deletion
EDAT- 1999/08/06 00:00
MHDA- 1999/08/06 00:01
CRDT- 1999/08/06 00:00
PHST- 1999/08/06 00:00 [pubmed]
PHST- 1999/08/06 00:01 [medline]
PHST- 1999/08/06 00:00 [entrez]
AID - 10.1038/sj.onc.1202759 [doi]
PST - ppublish
SO  - Oncogene. 1999 Jul 15;18(28):4144-52. doi: 10.1038/sj.onc.1202759.